Glitaray M Forte 3mg/1000mg Tablet is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production, increases peripheral glucose uptake, and improves insulin sensitivity without causing significant hypoglycemia. The synergistic action of these two agents helps achieve optimal blood glucose regulation in patients inadequately controlled by diet, exercise, or monotherapy. Glitaray M Forte is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely, hypoglycemia. Regular monitoring of blood glucose levels, renal function, and periodic assessment of glycemic control via HbA1c is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. This medication should be used under medical supervision to minimize risks and optimize efficacy.